Roche share price set for Monday test after MS drug fenebrutinib data lands
Roche Holding is drawing attention as Swiss markets reopen Monday, following word from the drugmaker that its investigational multiple sclerosis therapy, fenebrutinib, met its primary endpoint in a late-stage trial targeting primary progressive multiple sclerosis. Roche closed out Friday at 356.40 Swiss francs, down 0.6%.
